JP2013522222A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522222A5
JP2013522222A5 JP2012557231A JP2012557231A JP2013522222A5 JP 2013522222 A5 JP2013522222 A5 JP 2013522222A5 JP 2012557231 A JP2012557231 A JP 2012557231A JP 2012557231 A JP2012557231 A JP 2012557231A JP 2013522222 A5 JP2013522222 A5 JP 2013522222A5
Authority
JP
Japan
Prior art keywords
monocyclic
optionally substituted
compound
hydrogen
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012557231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522222A (ja
JP5888654B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/027817 external-priority patent/WO2011112766A2/en
Publication of JP2013522222A publication Critical patent/JP2013522222A/ja
Publication of JP2013522222A5 publication Critical patent/JP2013522222A5/ja
Application granted granted Critical
Publication of JP5888654B2 publication Critical patent/JP5888654B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012557231A 2010-03-10 2011-03-10 疾患の治療のためのヒスタミン受容体の複素環阻害薬 Expired - Fee Related JP5888654B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31261510P 2010-03-10 2010-03-10
US61/312,615 2010-03-10
PCT/US2011/027817 WO2011112766A2 (en) 2010-03-10 2011-03-10 Heterocyclic inhibitors of histamine receptors for the treatment of disease

Publications (3)

Publication Number Publication Date
JP2013522222A JP2013522222A (ja) 2013-06-13
JP2013522222A5 true JP2013522222A5 (enExample) 2014-04-24
JP5888654B2 JP5888654B2 (ja) 2016-03-22

Family

ID=44564108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557231A Expired - Fee Related JP5888654B2 (ja) 2010-03-10 2011-03-10 疾患の治療のためのヒスタミン受容体の複素環阻害薬

Country Status (18)

Country Link
US (1) US8569300B2 (enExample)
EP (1) EP2545058B1 (enExample)
JP (1) JP5888654B2 (enExample)
KR (1) KR20130016253A (enExample)
CN (1) CN102869666B (enExample)
AR (1) AR080496A1 (enExample)
AU (1) AU2011224316B2 (enExample)
BR (1) BR112012022211A2 (enExample)
CA (1) CA2791417A1 (enExample)
ES (1) ES2607125T3 (enExample)
IL (1) IL221829A (enExample)
MX (1) MX2012010404A (enExample)
NZ (1) NZ602041A (enExample)
PH (1) PH12012501783A1 (enExample)
RU (1) RU2012137180A (enExample)
TW (1) TW201200518A (enExample)
UY (1) UY33271A (enExample)
WO (1) WO2011112766A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039785A2 (en) * 2011-09-12 2013-03-21 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
CN105164134B (zh) 2013-05-02 2017-09-22 辉瑞大药厂 作为pde10抑制剂的咪唑并‑三嗪衍生物
LT3057586T (lt) 2013-10-18 2020-03-10 Celgene Quanticel Research, Inc. Bromodomeno inhibitoriai
ES2750956T3 (es) 2014-02-13 2020-03-30 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6602778B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Lsd1阻害剤としてのシクロプロピルアミン類
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
UY36462A (es) 2014-12-23 2016-07-29 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
BR112018002553A8 (pt) 2015-08-12 2023-01-24 Incyte Corp Sais de um inibidor de lsd1
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
CN109790166A (zh) 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
EP3472161B1 (en) 2016-06-20 2020-03-25 Novartis AG Triazolopyridine compounds and uses thereof
KR102519922B1 (ko) 2016-06-20 2023-04-11 노파르티스 아게 트리아졸로피리미딘 화합물의 결정질 형태
TW201837036A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物(一)
WO2018130443A1 (de) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
IL296456A (en) 2017-01-23 2022-11-01 Revolution Medicines Inc Bicyclics as allosteric shp2 inhibitors
KR20200036004A (ko) 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
SG11202002941WA (en) * 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
RU2020123241A (ru) * 2017-12-15 2022-01-17 Революшн Медсинз, Инк. Полициклические соединения в качестве аллостерических ингибиторов shp2
KR102614939B1 (ko) * 2018-02-13 2023-12-19 블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 피리미딘-융합고리 화합물 및 그의 제조방법과 용도
CN110655520A (zh) * 2018-06-29 2020-01-07 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
CN115448923B (zh) * 2018-02-13 2024-03-22 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
KR20200139153A (ko) 2018-02-27 2020-12-11 인사이트 코포레이션 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
EP3878853A4 (en) * 2018-11-07 2022-12-14 Shanghai Ringene BioPharma Co., Ltd. NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, METHOD OF PREPARATION AND USE
AU2019386036A1 (en) * 2018-11-30 2021-05-27 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP4019521A4 (en) * 2019-08-22 2023-05-03 Blueray Therapeutics (Shanghai) Co., Ltd AZAHETEROARYL COMPOUND AND USE
US12065444B2 (en) 2021-11-19 2024-08-20 Crossignal Therapeutics, Inc. Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929812A (en) * 1974-05-20 1975-12-30 Squibb & Sons Inc Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
JPWO2003028732A1 (ja) * 2001-09-28 2005-01-13 協和醗酵工業株式会社 受容体拮抗剤
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
JPWO2004000841A1 (ja) * 2002-06-25 2005-10-20 協和醗酵工業株式会社 二環性複素環化合物
EP1545532A2 (en) 2002-09-06 2005-06-29 Janssen Pharmaceutica N.V. Heterocyclic compounds
ES2317244T3 (es) * 2004-06-09 2009-04-16 Glaxo Group Limited Derivados de pirrolopiridina.
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
DE602007006010D1 (de) * 2006-05-31 2010-06-02 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
EP2044027A2 (en) * 2006-07-03 2009-04-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Fused bicyclic compounds interacting with the histamine h4 receptor
WO2008031556A2 (en) 2006-09-12 2008-03-20 Ucb Pharma, S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
EP2252619B1 (en) * 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
KR101589960B1 (ko) * 2008-02-08 2016-01-29 바실리어 파마슈티카 아게 Pde 억제를 통해 중재되는 질환의 치료를 위한 마크로라이드
UY32110A (es) * 2008-09-10 2010-04-30 Alcon Res Ltd Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad
CA2735369A1 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
ES2475091T3 (es) * 2009-04-16 2014-07-10 Centro Nacional De Investigaciones Oncol�Gicas (Cnio) Imidazopirazinas como inhibidores de proteína cinasas
EP2789614B1 (en) * 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
WO2011075591A1 (en) 2009-12-17 2011-06-23 Merial Limited Anti parasitic dihydroazole compounds and compositions comprising same
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
WO2011112687A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease

Similar Documents

Publication Publication Date Title
JP2013522222A5 (enExample)
AU2011238616B2 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
IL221829A (en) Heterocyclic inhibitors of histamine receptors for the treatment of the disease
CN1326848C (zh) 氨基吡唑衍生物
ES2673160T5 (es) Moduladores selectivos del receptor de la esfingosina 1 fosfato y métodos de síntesis quiral
KR102093608B1 (ko) 이미다조피리딘 화합물
ES2285784T3 (es) Derivados de pirazol.
JP5529124B2 (ja) 有機化合物
JP2010506825A5 (enExample)
JPH11335375A (ja) ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
BRPI0616567A2 (pt) compostos ativadores da atividade de glicoquinases, composição farmacêutica, bem como o uso dos referidos compostos
EP1758571A1 (en) Crth2 receptor ligands for therapeutic use
RU2019142795A (ru) Производное n-(азаарил)циклолактам-1-карбоксамида, метод его получения и его применение
JP2009508949A5 (enExample)
JP2017527578A5 (enExample)
RU2017135541A (ru) Гетероциклические амины и их применения
WO2014003153A1 (ja) 置換アミド化合物
TW200524575A (en) Biaryl linked hydroxamates: preparation and pharmaceutical applications
JP2008513508A (ja) 炎症及び免疫に関連する用途に用いる化合物
JP2013531055A (ja) プロテインキナーゼIKKε及び/又はTBK−1の阻害剤としてのピリミジン化合物、それらの製造方法及びそれらを含む医薬組成物
JP4528918B2 (ja) カルボキサミド誘導体
JP2008504304A5 (enExample)
JP2009541404A5 (enExample)
WO2001058880A1 (en) Novel triazole derivatives
RU2017112299A (ru) Способ получения ароматического гетероциклического соединения, применяемого в качестве селективного ингибитора киназы jak1, и применение ароматического гетероциклического соединения